AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05196698 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Flow Oxygen Therapy
Description: HFOT will be delivered validated medical devices and established as follow:~* Patient will be acclimatized to HFOT which will aim to achieve a flow of air of 30L/min at a temperature of 34°C using dedicated nasal canula.~* Once patient acclimatized, oxygen will be entrained in the HFOT device at a flow that will aim to achieve a saturation > 90%. An arterial blood gas will be performed with such oxygen delivery, flowrate and temperature to ensure a PaO2 ≥ 8kPa
Study NCT05196698 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Long-term oxygen therapy
Description: LTOT delivery will be performed according to French guidelines
Study NCT06083467 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Brain MRI Scan
Description: MRI scan of the brain
Study NCT06083467 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Neurologic exam
Description: Neurologic exam and assessments, including video interview
Study NCT05086068 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Arthrosamid
Description: Intra-articular hydrogel injection comprising of water and cross-linked polyacrylamide.
Study NCT05455762 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The intervention consists of 8 week of combined resistance and aerobic exercise. Patients will exercise 6 days a week;3 days aerobic ones and 3 days resistance ones. The aerobic exercise include 20 minutes of walking divided into three parts. In the first five minute the patients walks slowly to warm up, in the next 10 minutes the patient will speedup to reach the intensity described by the physiotherapist. In the last 5 minutes the patient walks like the first five minutes. The middle 10 minutes may be increased or not based on patient's weekly report. The resistance training consists of 5 exercise; hip abduction, shoulder abduction, bridging, elbow flexion and knee extension. each of these exercises is done in 3 set of 10 repetition with one minute break between each set. Based on patients' weekly report a 0.5 kilogram weight might be added.
Study NCT06329089 — intervention group
Intervention type: PROCEDURE
Intervention: Reoperative Sentinel Lymph Node Biopsy
Description: Reoperative sentinel lymph node biopsy refers to a surgical procedure performed when there is a need to re-examine the sentinel lymph nodes (SLNs) in patients who have previously undergone breast cancer surgery. The sentinel lymph nodes are the first lymph nodes to which cancer cells are likely to spread from the primary tumor. During the procedure, the surgeon locates and removes the previously identified sentinel lymph nodes using techniques such as lymphatic mapping and injection of a radiotracer or dye. The removed lymph nodes are then examined by a pathologist to determine if there is any evidence of cancer spread.
Study NCT06486805 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: the same volume of normal saline
Study NCT04910087 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Sonographic optic nerve sheath diameter measurement
Description: With the linear ultrasound probe operating at 11 MHz in B mode, it will be measured in 2 planes, 3.0 mm behind the optic disc, the transverse plane where the probe is placed horizontally and the sagittal plane where the probe is placed vertically. Then, the average of these measurements will be recorded for both eyes every 10 minutes.
Study NCT05991466 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: All patients will be assessed clinically and investigated for exclusion of any of the above-mentioned contraindications. The required laboratory work will be: complete blood count (CBC); prothrombin time and concentration (PT\&PC); partial thromboplastin time (PTT); bleeding time (BT); clotting time (CT); liver function tests and kidney function tests.~Before arrival to the operation room (OR), women will be premedicated by metoclopramide 10mg and ranitidine 50 mg intravenous. Intra operatively, hemodynamics will be recorded baseline before spinal anaesthesia , after its performance, every 3 minutes until delivery and then every 10 minutes till the end of the CS. Any change within 20% of baseline will be accepted and any changes more than 20% will be managed according to guidelines. All groups will be anaesthetized to preform CS with conventional spinal anaesthesia. The TAP block group will receive a landmark orientated Ultrasound guided bilateral TAP block.
Study NCT04889898 — intervention group
Intervention type: DEVICE
Intervention: Digital recording of speech and swallow sounds using the Beiwe Digital Health App on a personal smartphone
Description: \[Patients only\] Weekly completion of audio recordings of speech and swallowing performed at home by the subject using the study smartphone application on their personal device.
Study NCT04889898 — intervention group
Intervention type: RADIATION
Intervention: Modified Barium Swallow Study (MBSS)
Description: \[Patients only\] MBSS is an instrumented evaluation of oropharyngeal swallowing function that is performed using videofluoroscopy.
Study NCT04889898 — intervention group
Intervention type: BEHAVIORAL
Intervention: Speech Intelligibility Test (SIT)
Description: \[Patients only\] The SIT is a standardized test for measuring speech intelligibility.
Study NCT05763862 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Genetic testing
Description: Same information as details in the experimental arm.
Study NCT04889898 — intervention group
Intervention type: BEHAVIORAL
Intervention: SIT Scoring
Description: \[Listeners only\] Listeners will judge the intelligibility of speech recordings made by patients in the study.
Study NCT05574764 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cultivating Awareness and Resilience in Education (CARE)
Description: CARE provides teachers and staff with tools and resources to reduce stress, prevent burnout, enliven teaching, and help students thrive socially, emotionally, and academically. CARE blends instruction with experiential activities, reflection, and discussion.
Study NCT06290011 — intervention group
Intervention type: DEVICE
Intervention: Pain key group
Description: mixed real pain treatment software, pain treatment scenarios in MR
Study NCT05811533 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spencer's MET with conventional therapy
Description: Patients will be asked to lie in a side lying position with the affected shoulder above. The therapist will stabilize the shoulder girdle with the proximal hand and the distal hand provided force into the restrictive barrier of shoulder in 7 different movements. During all the movements, patients will ask to use their muscle energy 20% against the slight resistance offered by the therapist for 3-5 seconds. The patient then asks to relax and exhale after that shoulder joint will move beyond the barrier to achieve the next barrier. After 20 sec of rest, this technique will be repeated 3-5 times
Study NCT05811533 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post-Facilitation Stretch with conventional therapy
Description: Muscle Energy Technique \[Post Facilitation Stretch)\] for the shoulder joint will be applied with 3 repetitions per set, 1 session per day. Patient will be instructed to perform a full strength contraction of the muscle to be stretch for 10 seconds. The muscle is then allow to fully relax, whereupon a rapid stretch of the affected muscle will be performed and will held in position by the physician for 15 sec. Patient will be asked to relax and whole cycle will be repeated
Study NCT05715671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: esketamine
Description: The corresponding esketamine dose for each group was used at the end of anesthesia induction, and esketamine was changed to the corresponding maintenance dose for each group prior to surgical skin incision.
Study NCT05805358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperpolarized 13C-Pyruvate injection
Description: DNP-MRI for splenic immune function evaluation through hyperpolarized 13C-Pyruvate injection
Study NCT04870736 — intervention group
Intervention type: PROCEDURE
Intervention: Mout-to-mouth ventilation
Description: Chest rising during basic life support will be recorded as No breath (no visible chest rising) and Breath (chest rising) by the observer.
Study NCT04870736 — intervention group
Intervention type: PROCEDURE
Intervention: Mout-to-mouth ventilation with quantitative analysis
Description: Chest rising during basic life support will be recorded and evaluated (breath by breath) in QCPR Skill Reporter software
Study NCT05610085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam Injection
Description: Neonates will be treated with intravenous levetiracetam 60mg/kg for first line management of seizures, and if seizures persist will be randomized to receive higher dose Levetiracetam or standard of care phenobarbital
Study NCT05610085 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenobarbital Sodium Injection
Description: Standard of care for neonatal seizures
Study NCT05871983 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MUNICH TRANSCATHETER MITRAL VALVE REPLACEMENT SYSTEM
Description: The replacement valve consists of a self-expanding, tri-leaflet, dry bovine -pericardial valve. The dry tissue allows the valve to be conveniently pre-loaded. The key characteristics of Munich valve are:~* Nitinol stent frame~* Bovine pericardium~* Polyester skirt~* Anchoring system allows anchoring the frame to the annulus~* Hooks are used to reduce the mobility of the native leaflets and decrease risk of embolization.~The Munich TMVR system design proposed for this clinical investigation represents a significant evolution from previous TMVR designs:~* Transfemoral / transseptal access~* Self-expanding~* Dry pericardium (can be pre-loaded)~* No anchors~* 27 Fr delivery catheter (~* Sizes: 40/48/55mm~* Height 30 mm The valve is available in 3 sizes with a 30mm profile and has been designed to reduce the complexity of implantation in comparison to other TMVR systems.
Study NCT04698265 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human amniotic suspension allograft (ASA)
Description: Human amniotic suspension allograft (ASA) intra-articular injection.
Study NCT04698265 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Human amniotic suspension allograft (ASA)
Description: Human amniotic suspension allograft (ASA) intra-articular injection.
Study NCT05319093 — intervention group
Intervention type: DRUG
Intervention: Ozanimod
Description: Three-months, longitudinal observational period
Study NCT06331676 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tissue collection
Description: Eutopic and ectopic endometrium biopsies, additional blood and peritoneal fluid sampling
Study NCT06331676 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tissue collection
Description: Eutopic and ectopic endometrium biopsies, additional blood and peritoneal fluid sampling
Study NCT06331676 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Data collection
Description: Questionnaire on menstrual health and history of hormone treatments for the research purpose
Study NCT06331676 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Data collection
Description: Questionnaire on menstrual health and history of hormone treatments for the research purpose
Study NCT05263947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab and Icotinib
Description: Bevacizumab15mg/kg by intravenous drip infusion on day 1 of a 21-day (within 3 days) cycle; Icotinib orally twice daily at 250mg/day
Study NCT05245396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ref (TF2)
Description: Participants will receive 2 single oral doses of Ref (TF2) on Day 1 in treatment period 1, 2, or 3 of Part A, B, C and D.
Study NCT06253676 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem Management Plus (PM+)
Description: Validated across multiple low- and middle-income country settings, PM+ is World Health Organization-developed, five-session task-sharing intervention for mild to moderate distress. Per the (manualized) intervention, trained non-specialist providers coach eligible clients to address practical problems and/or distress in their daily lives via the use of fundamental cognitive behavioral strategies (e.g., deep breathing and stress management, behavioral activation, strengthening of social support, etc.).
Study NCT06253676 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Problem Management Plus (PM+)
Description: Validated across multiple low- and middle-income country settings, PM+ is World Health Organization-developed, five-session task-sharing intervention for mild to moderate distress. Per the (manualized) intervention, trained non-specialist providers coach eligible clients to address practical problems and/or distress in their daily lives via the use of fundamental cognitive behavioral strategies (e.g., deep breathing and stress management, behavioral activation, strengthening of social support, etc.).
Study NCT04967274 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Startling acoustic stimulus
Description: StartReact: involuntary triggering of a planed movement by a loud acoustic stimulus.
Study NCT04692493 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: targeted synthetic DMARD class
Description: Switching to a targeted synthetic DMARD (choice from targeted synthetic DMARDs; currently available are tofacitinib, baricitinib, upadacitinib) in people with active RA despite current treatment
Study NCT04692493 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: non-TNFi-biologic class
Description: Switching to a non-TNFi-biologic (choice from non-TNFi-biologics; currently available are rituximab, abatacept, tocilizumab, or sarilumab) in people with active RA despite current treatment,
Study NCT05509257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: Participants will receive a single oral dose in randomized, crossover fashion with a 2 week wash out period between interventions. Medication will be taken 2 hours prior the neuroimaging.
Study NCT05509257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive a single oral dose of medication in randomized, crossover fashion with a 2 week wash out period between interventions.. Medication will be taken 2 hours prior the neuroimaging.
Study NCT05834959 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: An Educational and Training Program
Description: Education and practical training program designed to evaluate the effects of training on movement confidence, low back dysfunction and changes in rates of lower back injury
Study NCT05463952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vepdegestrant
Description: ARV-471 will be administered orally QD with food, in continuous dosing over 28-day cycles.
Study NCT04877691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medi-546
Description: Patients will have IP administered or will self-administer IP under supervision by site staff at Week 0 and Week 1 and, for patients participating in the OLE period, at Week 52. For weekly doses coinciding with subsequent on-site visits, patients will also have IP administered or will self-administer IP under supervision by site staff, and in addition will receive a set of kits (including back-up kits) for at-home administration.
Study NCT04877691 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution for injection in aPFS
Study NCT05577065 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Single strain probiotic in the form of a sachet with a daily dose of 3E+9 Colony Forming Unit (CFU) per day for 26 weeks.
Study NCT05245396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evobrutinib MR-T1
Description: Participants will receive single oral dose of MR-T1 on Day 1 in treatment period 1, 2, and 3 of Part A.
Study NCT05245396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evobrutinib MR-T2
Description: Participants will receive single oral dose of MR-T2 on Day 1 in treatment period 1, 2, and 3 of Part A.
Study NCT05245396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evobrutinib MR-T3
Description: Participants will receive single oral dose of MR-T3 on Day 1 in treatment period 1, 2, and 3 of Part A.
Study NCT05245396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evobrutinib MR-T4
Description: Participants will receive single oral dose of MR-T4 on Day 1 in treatment period 1, 2, and 3 of Part A.
Study NCT05245396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evobrutinib MUPS-C1
Description: Participants will receive single oral dose of MUPS-C1 on Day 1 in treatment period 1, 2, and 3 of Part B.
Study NCT05245396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evobrutinib MUPS-C2
Description: Participants will receive single oral dose of MUPS-C2 on Day 1 in treatment period 1, 2, and 3 of Part B.
Study NCT05245396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evobrutinib MUPS-C3
Description: Participants will receive single oral dose of MUPS-C3 on Day 1 in treatment period 1, 2, and 3 of Part C.
Study NCT05245396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evobrutinib MUPS-C4
Description: Participants will receive single oral dose of MUPS-C4 on Day 1 in treatment period 1, 2, and 3 of Part C.
Study NCT05245396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evobrutinib MR-T adapated
Description: Participants will receive single oral dose of MR-T adapted on Day 1 in treatment period 1, 2, and 3 of Part D.
Study NCT05577065 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo in the form of a sachet once daily for 26 weeks
Study NCT05449132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RTX-GRT7039
Description: RTX-GRT7039 intra-articular injection.
Study NCT05449132 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching RTX-GRT7039 intra-articular injection.
Study NCT06344923 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ileostomy with a support rod instead of the layer of peritoneum and anterior rectus sheath suturing
Description: The terminal ileum about 30cm proximal to the cecum was recognized and was lifted out of the body through the auxiliary incision at the right lower abdomen and made sure that the ileum was not twisted. Appropriate sutures can be used to narrow the peritoneal incision, preferably by inserting one finger. A support rod, made of a 24# silicone drainage tube with a 1ml syringe was passed through the mesentery of the small intestine. The support rod was removed two weeks after surgery. It is appropriate that the ileum wall protruded from the epidermis by about 3cm. After suturing trocar sites, the loop ileostomy was opened along the longitudinal axis of the intestinal wall, and 4-0 absorbable suture was used to fix the stoma and subcutaneous tissue circumferentially with 16-20 stitches.
Study NCT06344923 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ileostomy with the layer of the peritoneum and anterior rectus sheath suturing
Description: The terminal ileum about 30cm proximal to the cecum was recognized and was lifted out of the body through the auxiliary incision at the right lower abdomen and made sure that the ileum was not twisted. Appropriate sutures can be used to narrow the peritoneal incision, preferably by inserting one finger. The seromuscular layer of the ileum or the mesentery was intermittently sutured with peritoneum and the anterior sheath of the rectus abdominis circumferentially with 8-10 stitches (3-0 silk thread). It is appropriate that the ileum wall protruded from the epidermis by about 3cm. After suturing trocar sites, the loop ileostomy was opened along the longitudinal axis of the intestinal wall, and 4-0 absorbable suture was used to fix the stoma and subcutaneous tissue circumferentially with 16-20 stitches
Study NCT04886037 — intervention group
Intervention type: OTHER
Intervention: sestrin
Description: Serum sestrin levels involved in inflammation and energy metabolism are compared between endometriosis and healthy control group.
Study NCT06576570 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Education presentation of surgical ergonomics
Description: During an individual meeting with participant, a brief presentation will be supplied for review.
Study NCT06576570 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Summary of Ergonomic Measurement System
Description: Participant will view a video of their movements with a visual guideline highlighting high-risk angles and movements.
Study NCT04681937 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Subacromial Injection (hyaluronic acid) + Physical Therapy.
Description: arm1: sodium hyaluronate (4ml) arm2: platelet-rich-plasma (4ml) arm3: methylprednisolone acetate (1ml methylprednisolone acetate + 3 ml serum saline) arm4: serum saline (4ml) The same physical therapy procedure will be applied to all arms after injection.
Study NCT04681937 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Subacromial Injection (Platelet-Rich-Plasma) + Physical Therapy.
Description: arm1: sodium hyaluronate (4ml) arm2: platelet-rich-plasma (4ml) arm3: methylprednisolone acetate (1ml methylprednisolone acetate + 3 ml serum saline) arm4: serum saline (4ml) The same physical therapy procedure will be applied to all arms after injection.
Study NCT04681937 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Subacromial Injection (methylprednisolone acetate) + Physical Therapy.
Description: arm1: sodium hyaluronate (4ml) arm2: platelet-rich-plasma (4ml) arm3: methylprednisolone acetate (1ml methylprednisolone acetate + 3 ml serum saline) arm4: serum saline (4ml) The same physical therapy procedure will be applied to all arms after injection.